Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. by Grigoriadis, Anita et al.
UCSF
UC San Francisco Previously Published Works
Title
Establishment of the epithelial-specific transcriptome of normal and malignant human 


















eScholarship.org Powered by the California Digital Library
University of California
Available online http://breast-cancer-research.com/content/8/5/R56Open AccessVol 8 No 5Research article
Establishment of the epithelial-specific transcriptome of normal 
and malignant human breast cells based on MPSS and array 
expression data
Anita Grigoriadis1, Alan Mackay2, Jorge S Reis-Filho2, Dawn Steele2, Christian Iseli3, 
Brian J Stevenson3, C Victor Jongeneel3, Haukur Valgeirsson2, Kerry Fenwick2, Marjan Iravani2, 
Maria Leao1, Andrew JG Simpson4, Robert L Strausberg5, Parmjit S Jat6, Alan Ashworth2, A 
Munro Neville1 and Michael J O'Hare1
1Ludwig Institute for Cancer Research/University College London Breast Cancer Laboratory, 91 Riding House Street, London, W1W 7BS, UK
2The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
3Office of Information Technology, Ludwig Institute for Cancer Research and Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
4Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Centre, New York, NY 10021, USA
5The J. Craig Venter Institute, 9704 Medical Center Drive, Rockville, MD 20850, USA
6Department of Neurodegenerative Disease, Institute of Neurology, London, WC1N 3BG, UK
Corresponding author: A Munro Neville, munroneville@f2s.com
Received: 17 Jul 2006 Revisions requested: 7 Aug 2006 Revisions received: 7 Sep 2006 Accepted: 2 Oct 2006 Published: 2 Oct 2006
Breast Cancer Research 2006, 8:R56 (doi:10.1186/bcr1604)
This article is online at: http://breast-cancer-research.com/content/8/5/R56
© 2006 Grigoriadis et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Diverse microarray and sequencing technologies
have been widely used to characterise the molecular changes in
malignant epithelial cells in breast cancers. Such gene
expression studies to identify markers and targets in tumour
cells are, however, compromised by the cellular heterogeneity of
solid breast tumours and by the lack of appropriate counterparts
representing normal breast epithelial cells.
Methods Malignant neoplastic epithelial cells from primary
breast cancers and luminal and myoepithelial cells isolated from
normal human breast tissue were isolated by immunomagnetic
separation methods. Pools of RNA from highly enriched
preparations of these cell types were subjected to expression
profiling using massively parallel signature sequencing (MPSS)
and four different genome wide microarray platforms. Functional
related transcripts of the differential tumour epithelial
transcriptome were used for gene set enrichment analysis to
identify enrichment of luminal and myoepithelial type genes.
Clinical pathological validation of a small number of genes was
performed on tissue microarrays.
Results MPSS identified 6,553 differentially expressed genes
between the pool of normal luminal cells and that of primary
tumours substantially enriched for epithelial cells, of which 98%
were represented and 60% were confirmed by microarray
profiling. Significant expression level changes between these
two samples detected only by microarray technology were
shown by 4,149 transcripts, resulting in a combined differential
tumour epithelial transcriptome of 8,051 genes. Microarray
gene signatures identified a comprehensive list of 907 and 955
transcripts whose expression differed between luminal epithelial
cells and myoepithelial cells, respectively. Functional annotation
and gene set enrichment analysis highlighted a group of genes
related to skeletal development that were associated with the
myoepithelial/basal cells and upregulated in the tumour sample.
One of the most highly overexpressed genes in this category,
that encoding periostin, was analysed immunohistochemically
on breast cancer tissue microarrays and its expression in
neoplastic cells correlated with poor outcome in a cohort of
poor prognosis estrogen receptor-positive tumours.
Conclusion Using highly enriched cell populations in
combination with multiplatform gene expression profiling
studies, a comprehensive analysis of molecular changes
between the normal and malignant breast tissue was
established. This study provides a basis for the identification of
novel and potentially important targets for diagnosis, prognosis
and therapy in breast cancer.Page 1 of 15
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COMP = cartilage oligomeric matrix protein; DTET = differential tumour epithelial transcriptome; ER = estrogen receptor; GO = Gene Ontology; 
GSEA = gene set enrichment analysis; HTR = human transcriptome database; IL = interleukin; MAPK = mitogen-activated protein kinases; MIAME 
= minimum information about a microarray experiment; MPSS = massively parallel signature sequencing; POSTN = periostin; PR = progesterone 
receptor; RT-PCR = reverse transcription PCR; SAGE = serial analysis of gene expression; TMA = tissue microarray; tpm = transcripts per million; 
VEGF = vascular endothelial growth factor; VEGFR = vascular endothelial growth factor receptor.
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Breast cancer is a clinically heterogeneous disease and con-
sists of many different cell types, including normal and reactive
stromal components in addition to the malignant neoplastic
compartment. Moreover, it comprises a series of distinct
malignant tumours that present diverse cellular features with
varying differentiation status, distinct genetic changes,
responses to therapy and outcome [1]. Likewise, the normal
breast is also composed of different parenchymal and stromal
cell types, with the terminal ductal-lobular unit being the most
important feature with regard to neoplasia. The latter is com-
posed of two morphologically recognisable cell types, epithe-
lial cells on the luminal surface and basally located
myoepithelial cells. While typical breast cancers have been
traditionally regarded as exhibiting characteristics akin to lumi-
nal epithelial cells, recent data have shown that some also
exhibit, in part or whole, myoepithelial/basal features [2-4].
Based on the restricted expression of genes representing the
phenotypes of luminal epithelial and basal cells [4], major sub-
types of breast cancer have been defined and linked to both
long term survival [5] and their response to therapy [6]. There-
fore, detailed characterisation of the normal luminal and
myoepithelial/basal phenotypes is a prerequisite for under-
standing the genetic alterations that occur in breast cancers
and how they may impact on disease progression and
outcome.
The use of solid tissues, as in most previous breast cancer
gene expression analyses, results in greatly enhanced com-
plexity of data because of the widely varying degrees of stro-
mal responses (desmoplasia) and inflammatory infiltrates in
individual tumours. Laser capture microdissection partially
alleviates this problem in respect to tumour samples, but is
unsuited to the large-scale separation of the normal epithelial
cell types in breast because of the close contact between
these cells. Immunomagnetic separation of individual cell
types from normal human breast tissue [7,8] and primary
breast cancers [9] has enabled direct comparisons of normal
epithelial and malignant epithelial cells to be made. Previous
proteomic [9,10] and gene expression analyses of such sam-
ples [10-13] have established a partial molecular characterisa-
tion of the epithelial compartment in the normal breast and
breast cancer [2], but, due to the limitations of technology
available at the time of these studies, did not provide a com-
prehensive comparison of all proteins or transcripts.
Multiple large-scale analytical techniques now make it possi-
ble to capture entire transcriptomes of defined cell popula-
tions. Breast cancers have been extensively analysed with
both expression arrays [14] and with direct sequencing tech-
niques such as serial analysis of gene expression (SAGE)
[15]. Although several studies have correlated expression data
based on microarray and SAGE [16,17], a comprehensive
genome-wide expression profile using a combination of com-
plementary technologies has not yet been achieved for puri-
fied malignant epithelial breast cells in comparison with
purified normal breast epithelial cells. In this study, massively
parallel signature sequencing (MPSS) [18,19] and multiple
genome-wide microarrays have been used to analyse immu-
nomagnetically separated normal luminal epithelial cells and
primary breast cancers substantially enriched for the neoplas-
tic epithelial component. The aim of this study was to establish
a virtually complete coverage of transcripts deregulated in the
neoplastic cells of human breast cancer. In addition, expres-
sion profiles from normal luminal and myoepithelial cells have
been used to identify cell-type specific transcripts and onto-
logically related gene sets in the differentially expressed
tumour epithelial transcriptome. The use of highly enriched cell
preparations in combination with a multiplatform approach to
their expression analysis has revealed novel markers and
potential targets, the clinical significance of some of which has
also been examined, using tissue microarrays.
Materials and methods
Sample preparation
Ten primary cultures (approximately 107) of normal human
breast luminal and myoepithelial cells were prepared from
reduction mammoplasty samples by double immunomagnetic
sorting methods [7,8,10]. In brief, breast epithelial cells were
immunomagnetically purified using combined positive mag-
netic activated cell sorting (MACS; Miltenyi Biotec, Auburn,
CA) selection with antibodies against the luminal epithelial
marker EMA (rat monoclonal ICR-2, Seralab, Leicestershire,
UK) and the myoepithelial membrane antigen CD10 (mouse
monoclonal CALLA clone SS2/36, DAKO Corporation, Glos-
trup, Denmark), followed by negative Dynabead (Dynal, UK)
selection using mouse monoclonal antibodies against anti-β-
4-integrin clone A9, a myoepithelial cell-surface antigen
(Santa Cruz Biotechnology, CA, USA) and BerEp-4 Epithelial
Antigen, a luminal antigen (DAKO Corporation, Glostrup, Den-
mark). Immunostaining with myoepithelial and luminal-specific
lineage markers showed the final sort of epithelial cells used in
this study to be >95% pure. Full details of these procedures
are not only contained in previous publications [10,11], but are
also appended, as required, to the Minimum information about
a microarray experiment (MIAME) protocol that accompanies
submission E-TABM-66 [20].
Malignant breast epithelial cells of 50 freshly isolated primary
infiltrating ductal carcinomas of histological grade 2 and 3
were enriched from disaggregated tumour tissue as described
previously [9]. In brief, fresh tumour biopsies (1 to 2 g) were
comminuted to approximately 1 mm3, using scalpel blades,
and subjected to a controlled disaggregation using 0.25%
collagenase Type1 (Sigma-Aldrich, Dorset, UK) in L-15Page 2 of 15
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shaking. After brief settling, the supernatant was spun down,
and the pellet resuspended in L-15 medium and passed
through a 100 µm mesh filter to remove residual undisaggre-
gated tumour fragments, plus disaggregated 'normal' orga-
noids and ducts as well as lobules and ducts distended with
ductal carcinoma in situ, leaving only small clusters and single
cells. The latter were then reacted with the mouse monoclonal
antibody F19 to fibroblast activation protein bound to sheep
anti-mouse coated Dynabeads (Dynal, Paisley, UK) using the
manufacturer's protocols. Almost all desmoplastic fibroblasts
associated with breast cancers express this antigen strongly.
Cells attached to beads were removed with a Dynal MP40
magnet; F19-negative cells were then allowed to sediment
under unit gravity for 2 to 3 h (to remove most lymphocytes).
The resulting preparation was then screened by phase con-
trast microscopy to identify those preparations in which there
were few if any microvessels (the other main potential stromal
contaminant not removed by fibroblast activation protein sort-
ing), or normal tissue elements, such as ducts or acini's. Of the
50 samples, 15 were selected for this study, based on the cri-
teria of ≥80% malignant cell content as determined by phase-
contrast examination, ≥80% viability (as determined by trypan
blue exclusion) and the integrity of its total RNA. The purity of
both normal and malignant epithelial preparations is illustrated
in Additional file 1. Informed consent to use this material for
scientific research was obtained, and details of the pathology
of the individual tumours are given as Additional file 2. RNA
was prepared from individual samples by standard Trizol meth-
ods and pooled to give a luminal, a myoepithelial and a malig-
nant RNA sample of >1 mg for analysis.
MPSS analysis
MPSS was performed by Lynx Therapeutics, (CA, USA)
according to the Megaclone 'signature' protocol [18,19].
Briefly for each library synthesis, after DNase treatment of
approximately 300 µg total RNA from normal luminal and
malignant breast epithelial pools, cDNA was generated from
poly(A)+ RNA, and amplified copies of each cDNA clone were
attached to beads. The sequence adjacent to the poly(A) prox-
imal DpnII site was determined by cycles of ligations to fluo-
rescently tagged 'decoding' oligonucleotides and cleavages
by restriction enzymes. Each sequence signature comprises
the DpnII restriction recognition site (GATC) and 13 contigu-
ous nucleotides. The raw data resulted from four sequencing
runs, collected in two reading frames offset by two nucleotides
relative to the anchoring restriction enzyme site and generat-
ing approximately 2 to 3 × 106 sequences. Signatures that
were seen in at least two independent runs (reproducible) and
were present at a frequency of more than three transcripts per
million (tpm) in one sample (significant) were selected for fur-
ther analysis.
As a basis for the matching of signature sequences to tran-
scripts, we used our own reconstitution of the human tran-
scriptome database (HTR) [21-23] based on a comprehensive
set of cDNA to genome alignments that are merged into gene
models representing the detailed structure of human tran-
scribed regions. Each HTR contains a cluster of cDNA
sequences, similarly to the NCBI/UniGene database. The
annotation of the signature was then performed in two steps
as described previously [22], using the NCBI35 assembly of
the human genome. Firstly, a 'signature-centric' annotation
was performed, where sequence signatures were mapped to
either one or more transcribed regions of the genome, includ-
ing repetitive sequences, ribosomal, mitochondrial and non-
mapped transcripts. In the second step, only signatures from
the 'signature-centric' annotation that matched exactly or had
one nucleotide mismatch to known transcribed regions were
retained to form the 'gene-centric' version. When different
sequence signatures mapped to the same gene, counts were
combined. To identify genes with significant differences (P
value ≤ 0.05) in representation in the two RNA pools, the
absolute difference in abundance between the malignant and
the normal epithelial RNA sample was determined and log2
transformed, resulting in a relative expression measurement.
Table 1
Numerical analysis of massively parallel signature sequencing
Malignant breast epithelium Normal luminal epithelium
Sequence signatures 24,288 28,404
Uniquely mapped signatures 14,245 10,249
Unique HTR clusters 8,421 (3,191)a 6,477 (1,297)a
Dynamic range <9,808 tpm <35,847 tpm
Differentially expressed transcripts 4,311 T > L 2,242 L > T
Sequence signatures represent the total number of sequences obtained by massively parallel signature sequencing (MPSS). Uniquely mapped 
signatures correspond to the total number of human transcriptome clusters identified and retained in the 'gene-centric' annotation. Unique human 
transcriptome database (HTR) clusters are transcripts that mapped to a single human cluster and had an abundance of ≥3 transcripts per million 
(tpm) (approximately one transcript/cell). As described in Materials and methods, statistically significantly (P ≤ 0.05) differentially expressed 
transcripts were determined and separated into tumour (T) over normal luminal (L) or vice verse, depending on their fold change. aCorresponds to 
HTR clusters found in only one sample.Page 3 of 15
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The same total RNA pools were hybridised onto a 20 k cDNA
microarray (20 k brk, constructed at The Breakthrough Breast
Cancer Research Centre, Institute of Cancer Research, Lon-
don, UK containing 19,391 sequence-validated IMAGE
clones), Affymetrix Human Genome U133 Plus 2.0 GeneChip
(Affymetrix, Inc., Santa Clara, CA, USA), CodeLink™ Human
Whole Genome Bioarray (GE, Healthcare, formerly Amersham
Biosciences, Chandler, AZ, USA) and Agilent Whole Human
Genome Oligo Microarray 44 k cDNA array (Agilent Technol-
ogies, Palo Alto, CA, USA). Three technical replicates of each
RNA pool were amplified, labelled and hybridised according to
manufacturer's guidelines. Where necessary an RNA pool
consisting of breast cancer cell lines was used as a reference
sample [11] and dye-swap hybridisations were performed. All
primary array data are available through ArrayExpress [20];
they comply with MIAME standards, with the accession
number E-TABM-66. Overlay of each microarray platform with
MPSS was done by mapping the sequence information of
probes and probe sets to the same HTR database as used for
MPSS tag mapping (see above). Only those microarray fea-
tures that were unambiguously mapped to a single HTR clus-
ter were included for further studies. All preprocessing of each
microarray platform and further statistical analysis was per-
formed in the R 2.1.1 environment [24] by making extensive
usage of the limma package [25] in BioConductor 1.6 [26].
For the Affymetrix platform, probe-level data were normalised
and expression data were summarised by the robust multi-
array analysis [27]; cyclic lowess normalisation was applied to
the CodeLink™ expression data through the codelink 0.7.2
package in R 2.3; for the Agilent microarrays, global normali-
sation with no background correction was applied; and for the
20 k brk microarrays, raw expression data were print-tip
normalised and background corrected. Relative measure-
ments for each transcript were given as a log2 fold ratio, and
only genes with a false discovery prediction of P ≤ 0.05 were
regarded as significantly differentially expressed when using
Benjamini and Hochberg' s P values adjustment [28].
Gene Ontology
Genes were categorised with respect to their biological proc-
ess, cellular role, molecular function, using Onto-Express (OE)
[29,30]. The most significant perturbed biological processes
were determined with respect to the number of genes
expected for each Gene Ontology (GO) category based on
their representation on the Affymetrix U133 Plus 2.0 array.
Statistical significance was determined by using OE's hyper-
geometric probability distribution and Bonferroni correction
options, and annotations with P ≤ 0.05 were accepted as sig-
nificant. Gene set enrichment analysis (GSEA) comparing
luminal and myoepithelial gene signatures was done using
described methods [31]. Biological processes were ranked
according to their significance of enrichment, and the valida-
tion mode measure of significance was used to identify those
of greatest enrichment.
Semiquantitative RT-PCR
Total RNA (10 µg) from the normal luminal epithelial and the
malignant epithelial RNA pool was used for each 40 µl
reverse-transcription reaction, and 10 µl of 1/50 diluted cDNA
Figure 1
Comparison of massively parallel signature sequencing (MPSS) data with microarray analysis. Differentially expressed gene profiles from MPSS 
(100%) were overlaid with each microarray platform individually. (a) Percentage of coverage (light grey) and concordance in differential expression 
between MPSS and individual arrays (dark grey) are shown together with the combined coverage and confirmation by at least one array (1 platform). 
(b) Enumeration of the differentially expressed transcripts detected by "MPSS-only", by "MPSS and array", and those transcripts reported as differ-
ential by at least two arrays, but not by MPSS ("Array only"). The results obtained by RT-PCR for these subgroups are shown below (see Additional 
file 6).Page 4 of 15
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Applied Biosystems AmpliTaq Gold, Cheshire, UK, with either
25 or 30 cycles, each consisting of 30 s at 94°C, 30 s at
55°C, and 45 s at 72°C. PCR products were visualised on 2%
Invitrogen agarose E-Gels 96 Gels (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA).
Immunohistochemistry and tissue microarray analysis
A cohort of invasive breast carcinomas from 245 patients
treated with surgery (wide local excision or mastectomy) and
adjuvant anthracycline-based chemotherapy was retrieved
from the Department of Histopathology files of the Royal
Marsden Hospital (London, UK) with appropriate local Ethical
Committee approval. Representative blocks were reviewed by
a pathologist (JSRF) and selected cores were incorporated in
two duplicate tissue microarray (TMA) blocks [32,33]. Full
details of the TMA are given as Additional file 3. TMA samples
were dewaxed in xylene, cleared in absolute ethanol and
blocked in methanol for 10 minutes. Antigen retrieval for carti-
lage oligomeric matrix protein (COMP) and IL8 was by boiling
slides in citrate buffer (pH 6) for 2 minutes in a pressure
cooker, after which they were blocked with normal horse
serum (2.5% for 20 minutes; Vector Laboratories VL, Burlin-
game, CA, USA) and endogenous biotin blocked by pre-incu-
bating with avidin (15 minutes) and biotin (15 minutes). They
were then incubated with anti-COMP antibody (1/50; Sero-
tec, Oxford, UK) or IL8 antibody (1/5; Serotec) for 1 h at room
temperature. For immunohistochemistry of Periostin (POSTN),
sections were pretreated by microwaving in Dakocytomation
(Glostrup, Denmark) pH 6 antigen retrieval buffer for 18 min-
utes, blocked, and anti-POSTN antibody (1/1500; Biovendor
Laboratory, Heidelberg, Germany) applied for 30 minutes at
room temperature. Antibody binding was detected using
Vectastain Universal ABC (VL), visualised with 3,3'-diami-
nobenzidine DAKO (Corporation, Glostrup, Denmark). Full
details on the distribution of ER, PR, HER2, EGFR, CK 14, CK
5/6, and CK 17, as well as P53 (DO7, 1/200; DAKO Corpo-
ration) are described elsewhere [33] and summarised in Addi-
tional file 3. To evaluate the proliferative activity of tumour cells,
immunohistochemical detection of MIB1 antibody to detect Ki-
67 nuclear antigen (1/300; DAKO Corporation), which is
associated with cell proliferation, was carried out under the
same conditions [33]. For these markers, only nuclear staining
was considered specific. Ki67 (MIB1) staining was scored low
if less than 10% of neoplastic cells were positive, intermediate
if 10% to 30% of neoplastic cells were positive and high if
more than 30% of neoplastic cells were positive [32].
Tumours were scored positive for P53 if >10% of the nuclei of
neoplastic cells displayed strong staining [32].
Cumulative survival probabilities were calculated using the
Kaplan-Meier method/log-rank test. Differences between dis-
ease-free interval and survival were tested with the log-rank
test (two-tailed, confidence interval 95%) using the statistical
software Statview 5.0., NC, USA. Multivariate analysis was
performed using the Cox multiple hazards model. A P value <
0.05 in the univariate survival analysis was used as the limit for
inclusion in the multivariate model.
Results
MPSS analysis of normal luminal and malignant breast 
cancer cells
The gene expression profiles that were obtained by MPSS
analysis yielded 24,288 and 28,404 signature sequences for
the malignant and the normal breast epithelium, respectively;
these were pared down to the 'signature-centric' version con-
taining 14,245 uniquely mapped and expressed transcripts for
the malignant sample and 10,249 transcripts for the normal
luminal epithelial sample (Table 1). Based on our HTR
(described in Materials and methods [21]), these transcripts
corresponded to 8,421 and 6,477 HTR clusters in the malig-
nant and the normal RNA samples, respectively (Table 1), of
which 3,191 genes were uniquely expressed in the malignant
sample, and 1,297 in the normal sample. To define differential
expression, a comparative Poisson test was applied [34] and
6,553 genes were identified that showed a differential expres-
sion measurement with P ≤ 0.05. (Raw and annotated MPSS
data are provided as Additional file 4) Expression levels of dif-
ferentially upregulated transcripts in the tumour sample
ranged from less than 10 tpm (ESR1, EGF, GPR150,
GADD45BGIP1), to over 1,000 tpm (COL1A1, SCGB2A2,
SELE, IL8).
Establishing a microarray validated transcriptome
The MPSS derived transcriptomes were compared with gene
expression profiles of the same RNA pools obtained using
three oligonucleotide genome-wide microarrays, Affymetrix
U133 Plus 2.0 GeneChip and CodeLink™ Human Whole
Genome Bioarray, Agilent Whole Human Genome Oligo
Microarray 44 k cDNA array and 20 k brk cDNA microarray.
These different microarray platforms were chosen to achieve
the highest possible coverage of known transcribed
sequences. Features from all platforms were mapped to HTR
clusters and our analysis was restricted to those that mapped
unambiguously to one HTR cluster. For the Affymetrix platform
41,322 of 54,613 (75.66%) features could be assigned to
unique HTR clusters; for CodeLink™ 28,949 of 54,841
(52.78%); for Agilent 32,402 of 44,290 (73.15%); and for the
20 k brk 12,055 of 19,959 (60.4%). Overlay of the transcript
coverage of each microarray demonstrated that each platform
contributed a set of unique genes as well as those common to
other platforms, justifying the use of more than one microarray
platform. (Full annotation of each microarray platform to HTR
clusters is available as Additional file 5) The microarray fea-
tures of all four platforms provided a total coverage of 26,103
HTRs, and 6,342 out of 6,553 (96.8%) of the differentially
expressed transcripts obtained by MPSS were represented
on one or more of these genome-wide platforms.Page 5 of 15
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annotation, those genes reported as differential between the
normal and malignant tumour sample by microarrays were
defined and then compared with the MPSS data. The criteria
for differential expression used were that expression measure-
ments between the normal and the malignant sample reported
had to be both statistically significant (P ≤ 0.05) and in the
same direction (up or down). Out of the four microarray plat-
forms, the two single colour oligonucleotide platforms
(Affymetrix and CodeLink™) validated as differential 3,206
(48.9%) and 3,004 (45.8%) of all MPSS transcripts present
on their platforms, respectively, whereas the two-colour micro-
array technologies confirmed only 1,257 (19.1%) and 1,379
(21%), for Agilent and 20 k brk, respectively (Figure 1a). Over-
all, a total of 3,902 genes were obtained in which at least one
microarray confirmed the MPSS data without any other plat-
form reporting an opposite result (Figure 1a; 1 platform).
Expression measurements for 2,440 MPSS differential tran-
scripts could not be confirmed using any of these microarray
platforms (Figure 1b, "MPSS-only"). The microarray data were
also used to identify any genes reported as differential by at
least two platforms, but which did not appear as such in the
MPSS analysis. This comprised a total of 4,149 transcripts
(Figure 1b, "Array-only"). To establish which of those sets
could be most relied on to constitute the validated differential
tumour epithelial transcriptome (DTET), examples of each
group were analysed by semi-quantitative RT-PCR (Figure
1b). This showed that only 30% (6/20) of the "MPSS-only"
identified differentials could be validated, while 78% (78/100)
and 92% (37/40) of the "MPSS and array" and "Array-only"
differentially expressed transcripts were reported as differen-
tial by RT-PCR (Additional file 6). The comparison of RT-PCR
results was not given any statistical treatment and is simply
presented to illustrate that the array confirmed differentials
have a much lower false positive rate (20% to 70%). Conse-
quently, the latter two groups were combined and comprised
8,051 up- and down-regulated genes that constitute the DTET
and were subjected to further analysis (Additional file 7).
Functional classification of differentially expressed 
genes
GO classification of the 8,051 genes of the DTET revealed
that, as might be expected, multiple cellular processes, such
as transcription, signal transduction, cell adhesion, cell cycle,
metabolism, transport and development, are different in normal
luminal epithelium and their malignant counterparts (the full list
of perturbed biological processes is provided as Additional file
8). In terms of overall differences, the largest functional group
of up-regulated transcripts (Figure 2a) corresponded to genes
associated with transcription and regulation in transcription, in
agreement with several other profiling studies. The second
largest functional group comprised genes involved in signal
transduction. These consisted, amongst others, of genes
encoding proteins involved in mitogen-activated protein
kinases (MAPK) signalling (FGF4, -7, -13, IL1A, IL1B, NGFB,
TGFB1 and TGFB3) and the JAK-STAT signalling pathway
(IL6, IL10, OSM, SPRY2), as well as ligands and receptors
involved in cytokine-cytokine interaction, including members of
the CXC and CC chemokines, platelet-derived growth factor,
gp130, tumour necrosis factor and transforming growth fac-
tor-β subfamilies. Many of these genes have already been cor-
related with breast cancer growth and invasion, and their
epithelial expression has been demonstrated. In contrast to
previously published SAGE data, comparing purified normal
Figure 2
Functional classification of the differentially expressed epithelial tumour transcriptome. The top 15 biological processes showing overall (a) up-regu-
lation and (b) down-regulation are shown. The biological processes are ranked from top to bottom according to their ascending P value as 
described in the Materials and methods. The numbers of genes within each process that are up-regulated or down-regulated for each category are 
also shown as black and grey bars, respectively.Page 6 of 15
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Heatmap of the top 50 genes from the luminal-specific and myoepithelial-specific transcriptomes. Genes were ranked in order of fold change 
(myoepithelial over luminal) for each platform separately after which a median rank over all four platforms was determined. Genes are listed with their 
human transcriptome database (HTR) cluster, HUGO Name, description and UniGene and RefSeq identifiers. Green corresponds to luminal-type; 
red to myoepithelial-type; black indicates no corresponding microarray feature. Expression measurements obtained by: 1, Agilent; 2, 20 k brk; 3, 
CodeLink; 4, Affymetrix platform.Page 7 of 15
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in which reduced expression of cytokines such as IL6 and IL8
was observed, higher abundance of these genes was
detected in our malignant breast epithelial sample in compari-
son with the normal luminal sample. Ninety genes belonging to
the GO category of 'apoptosis', including members of the
BAG family (BAG1, BAG2, BAG3), as well as members of the
breast cancer 'proliferation signatures' (BUB1, PLK1,
CCNE1, CCND1 and CCNB1) were also identified as up-
regulated in our DTET [35,36].
The most significantly perturbed functional gene set identified
in the down-regulated tumour epithelial transcriptome (Figure
2b) was epidermis development, including members of the kal-
likrein family (KLK5, KLK7, KLK8, KLK10) and the keratin fam-
ily (CK10, CK14), as well as the family of extracellular matrix
glycoproteins, such as LAMC2, LAMB3 and LAMA3. The
second most perturbed subset of down-regulated genes
included several members of the RAS-related proteins,
RAP1A, RALB, RAB5B, RAB4A, RAB3B, RAB2 and RAB25
(protein transport; Figure 2b), some of which counteract the
mitogenic function of RAS-MAPK signalling pathways [37].
Differentially expressed transcripts in normal breast 
epithelial cells
Whether tumours exhibit a luminal or myoepithelial/basal phe-
notype has been correlated with prediction and prognosis in
breast cancer [2-4]. Global transcriptomes of normal myoepi-
thelial and luminal epithelial cells were, therefore, compared to
identify all transcripts that were differentially expressed in
these normal cell types. The purpose was to further define
breast epithelial specificity within the tumour transcriptome by
annotating the DTET with respect to their expression in these
normal epithelial cell types. Differential gene expression pro-
files of immunomagnetically purified luminal and myoepithelial
cell samples were established using the criterion of differential
detection by at least two of the four genome-wide microarray
platforms, as used previously when comparing the normal
luminal with the malignant sample. We identified 907 tran-
scripts with higher abundance in the normal luminal cells and
955 transcripts were higher in the normal myoepithelial cells.
These collectively comprised the differential normal epithelial
transcriptome. The top 50 discriminator genes over all four
microarray platforms are shown in Figure 3 (complete list is
given as Additional file 9). These genome-wide gene signa-
tures agreed with previous data from individual luminal and
myoepithelial sample analyses [11]. All the main classifiers for
the myoepithelial cell type, such as LGALS7, S100A2, SFN,
SPARC and CAV1 (and CD24, LCN2, CLDN4, MUC1 and
SEMA3B for the luminal epithelial cell type) were identified as
differential in the present study. However, as expected from
the enhanced coverage provided by the methods used here,
many other genes that may play an important role in the biol-
ogy of these two cell types were also identified (for example,
PADI2, TSPAN2, DACT1 for the luminal, and POSTN, DCN,
ADAMTS5 for the myoepithelial cell type).
Figure 4
Enrichment of luminal and myoepithelial transcripts in the differentially expressed epithelial tumour transcriptomei i ll  it li l t r tr ri t . (a) The top 20 deregulated biolog-
ical processes identified by gene set enrichment analysis that are enriched in luminal (green) and myoepithelial (red) expression are shown. The def-
inition of each Gene Ontology (GO) category is given in Additional file 8. (b) Heatmap of the skeletal developmental gene subset (GO:0001501) 
based on the Affymetrix expression data. L (luminal) and M (myoepithelial) show results from individual arrays. Genes are ranked according to their 
significance of enrichment as described in the Materials and methods.Page 8 of 15
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To identify functionally related gene sets of luminal or myoepi-
thelial phenotype within the DTET, GSEA was carried out on
the perturbed biological processes that were statistically sig-
nificant (P ≤ 0.05) and composed of at least 10 genes [31].
This resulted in a total of 72 gene sets, 53 and 19 for the up-
and down-regulated modules, respectively (Additional file 8).
In the top 20, four categories showed enrichment of genes
belonging to our luminal transcriptome, including protein mod-
ification (GO:0006464), cell motility (GO:0006928) and pro-
tein dephosphorylation (GO:0006470), as down-regulated
modules, as well as antimicrobial immune response
(GO:0019735) as an up-regulated one (Figure 4a). Overall,
GSEA analysis showed marked enrichment for the expression
of myoepithelial genes in the functional groups of the tumour
overexpressed transcripts compared to the luminal epithelial
transcriptome (Figure 4a). The gene set with the most statisti-
cally significant representation of myoepithelial type genes
consisted of members of the collagenase family
(GO:0006817), with COL3A1, COL6A1, COL1A1,
COL5A12, COL15A2, COL1A1 and COL12A1 representing
the discriminator genes. The second most statistically signifi-
cant enrichment of expression in myoepithelial type genes with
higher abundance in the malignant breast epithelium was
found in the functional category of skeletal development
(GO:0001501; Figure 4a,b). This set of bone related genes
included COL1A2, COL1A1, GHR, COL12A1, PAPSS2,
TBX3, FRZB, EXT1, MSX1, EN1, TWIST1 and AEBP1, with
POSTN being the most prominent discriminator of this gene
set (Figure 4b).
Clinical significance of POSTN using tissue microarray 
analysis
To evaluate whether the luminal and myoepithelial annotations
of our epithelial deregulated transcriptome identify genes with
any correlation with clinical outcome in breast cancer, we per-
formed immunohistochemical analysis POSTN on a tissue
microarray consisting of 245 primary breast tumours. POSTN,
usually expressed in mesenchymal cells, was chosen, not only
because it was one of the most highly differentially expressed
genes in normal myoepithelial cells over all microarray plat-
forms (Figure 3), but also because it belongs to the functional
group of skeletal development that showed overall myoepithe-
lial-specificity and up-regulation in the malignant breast epithe-
lium (Figure 4b). When POSTN expression was examined at
the protein level, no detectable expression was observed in
the normal breast epithelium, but only in the stroma, in
concordance with its known mesenchymal expression (not
shown). However, 42/224 (18.75%) invasive breast carcino-
mas clearly showed epithelial expression (Figure 5a), whereas
the remainder showed the expected expression pattern only in
the stroma (Figure 5b). POSTN expression in neoplastic cells
was significantly correlated with positivity for progesterone
receptor (PR) (P < 0.05) and low proliferation rates as defined
by Ki67 (MIB1) staining (P < 0.05) (Additional file 10). When
the whole cohort was analysed, POSTN-positive breast can-
cers showed a trend towards a poorer outcome, although this
did not reach statistical significance (Additional file 11a,b).
Since the estrogen receptor (ER) status is the most important
marker in defining the prognosis and treatment of breast can-
cer, the correlation of POSTN expression with overall survival
and disease free survival was analysed in ER-positive and ER-
negative subgroups. No significant correlation was observed
in the ER-negative cohort. However, within the ER-positive
subgroup, 20.8% (37/178) of breast tumours were positive
and there was a significant correlation with both overall sur-
vival (P = 0.0083) and disease-free survival (P = 0.0136) (Fig-
ure 6a,b, respectively). In this cohort, modified Bloom-
Richardson grade (P < 0.01), lymph node status at diagnosis
(P < 0.005) and POSTN expression (P < 0.05) were statisti-
cally significant predictors of disease-free survival in univariate
analysis, whereas only lymph node status at diagnosis (P <
0.001) and POSTN expression (P < 0.01) were associated
with overall survival in univariate analysis. By multivariate anal-
ysis of disease-free survival in the ER-positive cohort, POSTN
did not reach formal statistical significance as an independent
factor (P = 0.0833) (Table 2, italics), although it did constitute
an independent prognostic factor for overall survival (P =
0.0168) (Table 2, bold). Two other genes that showed up-reg-
ulation in the malignant breast epithelium were also analysed
on the protein level by tissue microarray, namely those encod-
ing COMP [38], a skeletal developmental protein that was not
Table 2
Multivariant proportional-hazard analysis
Parameter Hazard ratio (95% confidence interval) P (Cox)
Grade 2.6434 (1.3935–5.0144) 0.0029
LN status 3.6408 (1.5264–8.6840) 0.0036
POSTN 1.8099 (0.9247–3.5422) 0.0833
LN status 5.6924 (1.3331–24.3076) 0.0189
POSTN 2.8151 (1.2048–6.5775) 0.0168
The tissue microarray cohort was analysed using the Cox proportional hazards model for disease-free survival (italic) and overall survival (bold). 
Only those statistically significant independent prognostic factors as determined by the model are shown. LN, lymph node status at diagnosis.Page 9 of 15
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cells, and IL8, an inducer of bone resorption. Similarly to
POSTN, COMP and IL8 could be clearly detected in the epi-
thelial cells of 21% and 13.9% invasive breast carcinomas,
respectively (Figure 5c,d). In contrast to POSTN, however,
there was no correlation of COMP or IL8 tumour staining with
age, grade, stage, ER, PR, disease-free interval or overall sur-
vival, although epithelial expression of the mesenchymal mark-
ers POSTN and COMP correlated significantly with each
other (Additional file 10).
Discussion
Using highly enriched populations of malignant breast epithe-
lial cells and normal epithelial cells, obtained from immu-
nomagnetic cell sorting, we have established genome-wide
molecular signatures specific to the epithelial compartments
of both the normal and the malignant human breast. Combin-
ing gene profiles obtained from different expression platforms,
including direct high-throughput sequencing (MPSS) and mul-
tiple microarray platforms, yielded a validated transcriptome
comprising 8,051 differential transcripts. These data provide a
basis for the molecular changes that occur in the transition
from normal luminal to malignant epithelial cells, and also allow
further analysis of solid breast tumour (neoplastic plus stroma)
gene expression studies, enabling those genes of specific epi-
thelial origin to be identified in respect to progression, predic-
tion of outcome and metastasis. The expression data obtained
from the normal luminal and myoepithelial cells have extended
our previous analysis of these normal cell types [11], and
provide gene sets that can be used to comprehensively spec-
ify the epithelial phenotype expressed in breast tumours, as
well as defining new markers of each cell type.
The data presented here report for the first time the application
and validation of the MPSS sequencing technology to malig-
nant human breast epithelial cells and their normal counter-
parts. MPSS expression studies of different human cell lines
and normal tissues have already shown that this technology
represents the most comprehensive sequencing methodology
available at present, in terms of gene coverage and quantita-
tive assessment of gene expression [22,39]. With over 106
sequencing reactions per sample [18,19], it is comparable in
scope with the now commonly used genome-wide microarray
profiling methods, as also used in the present study. Compar-
ative studies of genome wide data sets are entirely dependent
on the choice of common denominator for annotation [40]. By
using our sequence based mapping, 97% of MPSS tags
could be aligned with individual features on genome-wide
microarrays, indicating that the vast majority of the expressed
sequence tags in the normal and malignant breast epithelium
MPSS libraries represent known transcripts, in agreement
with the recent data suggesting that MPSS identifies very few
truly novel genes [39]. Given the significant methodological
differences between microarray and MPSS analysis, the fact
that more than 65% of our MPSS differential data set showed
concordance with expression profiling obtained by several dif-
ferent microarray platforms, represents a good overlap
compared with other examples of sequence versus array data
[41]. However, a substantial number of differentially expressed
genes (4,149) measured on at least two microarray platforms
were not identified as such by MPSS, and a significant number
of MPSS differential transcripts (2,440) were not confirmed
on any array (Figure 1), implying a relatively high false positive
and false negative rate of the MPSS methodology. This prob-
ably reflects the known limitations of the MPSS technology
[39], particularly with regards to transcripts that were not
detected (zero counts) in one sample, as well as genes lacking
appropriate restriction enzyme sites required for this technol-
ogy. However, individual microarray platforms themselves dif-
fer substantially [42] and a multiplatform approach, as used
here, clearly defines a robust DTET seen by every technology.
Another important feature of our DTET is the use of purified
epithelial cells, derived by both positive and negative immu-
nomagnetic sorting in which the contamination of malignant
samples with stromal cells is reduced to a minimum, and nor-
mal luminal and myoepithelial cells are separated from short-
term primary cultures. Although the profiling techniques used
represent the global transcriptomes of purified normal and
neoplastic breast epithelial cells in highly enriched prepara-
tions, it is conceivable that even a small contamination of the
Figure 5
Immunohistochemical analysis of periostin (POSTN), IL8 and cartilage oligomeric matrix protei  (COMP)
oligomeric matrix protein (COMP). (a) POSTN-positive invasive ductal 
carcinoma (IDC; ×400), in which both epithelial and stromal cells show 
cytoplasmic expression. (b) POSTN-negative IDC in which only the 
spindle shaped stromal cells are stained (×400). (c) IL8 (×100), show-
ing positive staining only in the malignant breast epithelial cells. (d) 
COMP expression in the epithelial and stromal cells of an IDC, showing 
strong expression in both stromal and epithelial cells (×100).Page 10 of 15
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as the induction of inflammatory genes due to in vitro manipu-
lation, could result in false positives. However, verification of
the probable epithelial origin of differentially expressed genes
can be obtained by comparing expression data from breast
epithelial cell lines [22], breast tumour cell lines or, as in the
present study, by immunohistochemistry, all of which show
that, for example, IL8, is a bona fide epithelial tumour-associ-
ated product [43,44]. One of the features of normal luminal
epithelial cultures is the loss of estrogen receptor expression
[45]. The microarray gene expression profiling currently used
to classify breast cancers supports the paradigm that ER sta-
tus is the most important phenotype in breast cancer and has
led to the classification of breast cancers into luminal A (ER-
positive good prognosis) and luminal B (ER-positive poor
prognosis), and ER-negative myoepithelial/basal and HER2
subtypes, each with distinct differences in prognosis and
response to therapy [4,5,46]. Genes identified in this study
representing the normal luminal epithelial phenotype are dis-
tinct from the subset of genes that are associated with ER
expression and are used to classify 'luminal' breast tumours.
Thus, we are able to define the luminal phenotype independ-
ently of ER status. In contrast, our myoepithelial signature con-
tains several members of the previously reported gene clusters
identifying basal-like breast cancers. Some of these have been
previously identified as myoepithelial genes in the normal
breast epithelium, for example, TIMP3, SPARC, JAG1,
PRSS11 and CAV-1 [11], and some of them, such as
S100A7, SPARC and CNN1, have previously been shown
individually to be correlated to poor outcome [5,11,47]. Since
our cell type specific gene signatures were derived from phe-
notypically well characterised cell types compared to empirical
stratification based on expression data, we were also able to
identify a range of myoepithelial type genes in ER-positive
tumours as well as those in basal-like breast cancers. Thus,
although the majority of the primary breast tumours within our
malignant pool were ER-positive 'luminal' tumours, a
significant number of up-regulated gene sets also showed
myoepithelial expression. The observation of myoepithelial
genes such as SFRP2, DCN, POSTN, LUM, COL1A2 and
COL11A1, which showed higher expression in ER-positive
compared to ER-negative breast tumours in two other breast
cancer tumour profiling studies [48,49], proved the value of
such an approach and demonstrated the heterogeneity of
breast tumours with respect to the levels of luminal epithelial
and myoepithelial gene expression. The potential clinical sig-
nificance of the expression of myoepithelial/basal genes in ER-
positive tumours has been highlighted by recent data showing
that the promoter DNA methylation of the classic myoepithelial
marker S100A2 is correlated with a poor prognosis in ER-pos-
itive tumours [50]. In contrast, increased levels of expression
of phosphoserine aminotransferase (encoded by PSAT1),
which was another gene also identified in our myoepithelial
transcriptome, was the strongest predictive marker for a poor
response to tamoxifen therapy in ER-positive tumours [50].
Our observation that the malignant epithelial expression of
POSTN, also a myoepithelial/basal gene, is associated with
poorer survival (P = 0.0083) in ER-positive tumours
demonstrates that the normal epithelial annotation of tumour
transcripts can identify many other types of myoepithelial/
basal genes, including those associated with a poor outcome.
An important question is whether the expression of myoepithe-
lial/basal genes in breast cancers are responsible for the prog-
nosis and poor response to therapy or are merely surrogate
markers thereof. There are several lines of evidence to suggest
that POSTN may play a role in the biology of breast cancer
[51,52]. POSTN is a ligand of αvβ3 integrins and promotes
adhesion and migration of epithelial cells [51]. Clinical studies
of periostin expression in human cancers have demonstrated
Figure 6
Cumulative Kaplan-Meier curves for epithelial expression of periostin (POSTN)i f ri ti  ( ). A cohort of poor-prognosis estrogen receptor (ER)-positive tumours 
was analysed showing: (a) a significantly shorter overall survival (P = 0.0083); (b) a shorter disease free survival (P = 0.0136).Page 11 of 15
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angiogenesis and metastasis [52-54]. In primary breast
tumours, POSTN causes up-regulation of vascular endothelial
growth factor receptor (VEGFR)-2 in endothelial cells [52].
Elevated expression of VEGFs, the ligands for the VEGF
receptors, as observed in some breast carcinomas as well as
in our study, provides synergistic paracrine signalling through
VEGFR-2 on endothelial cells, potentially promoting angiogen-
esis and dissemination. Although the expression of POSTN
shows a weak correlation with Ki67 immunoreactivity, there is
no evidence to suggest that POSTN itself influences prolifera-
tion or is a surrogate marker of proliferation rate. Rather, it
seems more likely that that its prognostic significance may be
due to the altered therapeutic responses of POSTN positive
tumours to drugs like tamoxifen. The fact that tumour-specific
expression of VEGFR-2 has been associated with an impaired
response to tamoxifen therapy in ER-positive premenopausal
breast cancer [55] is in line with the poor prognosis of this
cohort of breast cancers. Therefore, further studies are
required to investigate if POSTN positivity is correlated with
VEGFR-2 expression, thereby providing a molecular mecha-
nism that links POSTN to endocrine resistance for ER-positive
breast tumours.
Metastasis to bone occurs frequently in advanced breast can-
cer and is accompanied by debilitating skeletal complications
[56]. Among the up-regulated gene sets in the malignant sam-
ple with enrichment in myoepithelial/basal type genes in this
study was a small family of genes involved in bone remodelling
and skeletal development. Their expression in the human
breast epithelial cells, including the normal myoepithelial cells,
indicates that they play a significant role in epithelial cell biol-
ogy, in addition to mesenchymal development. Many of these
mesenchymal-specific genes, associated with osteoblasts,
have previously been found overexpressed in other primary
breast tumours [57]. By acquiring the expression of such mes-
enchymal genes, the malignant epithelial breast cells may have
an advantage in growth in the bone environment correlating
with progression into a more aggressive cancer phenotype.
Targeting such genes and proteins might, therefore, be a
means of suppressing this phenomenon.
Conclusion
In the past decade, several different expression and proteom-
ics studies on purified cell populations of normal luminal and
myoepithelial, as well as tumour enriched cell populations,
have been carried out [11-13,58,59]. Genes characterising
these cell types have been identified, some of which showed
altered expression levels in the malignant compared to the nor-
mal breast epithelium. In this study, we have taken this profiling
forward by comprehensively defining the transcriptomes of
highly enriched normal and malignant breast epithelial cell
populations on a genome wide scale using multiple technolo-
gies. We present here, for the first time, co-regulated breast
tumour-associated gene sets enriched in either luminal or
myoepithelial-type genes. These data are important for evalu-
ating the breast cancer stratification systems based on estab-
lished expression profiling, in which luminal and basal
phenotypes have been shown to be prognostically significant.
Further analysis of these related gene subsets, including
expression studies in individual tumours, will assist in our
understanding of the mechanisms involved in the initiation and
progression of breast cancer, and the loss or acquisition of
luminal or myoepithelial phenotypes in breast tumours. This
will lead to the identification of additional luminal and basal
markers and targets, with importance in the biology of breast
cancer and its treatment.
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Additional file 1
A jpeg figure showing cell separation of normal and 
malignant breast epithelial cells. Purity of separated 
normal and malignant cells. (a) A short-term primary 
culture of breast epithelium stained with monoclonal 
antibodies specific for vimentin (green), CK 14 (red), CK 
18 (blue) and CK 19 (purple), as visualised with 
appropriate class and sub-class specific fluorescence 
conjugated secondary antibodies (×150). The middle 
and right columns show the double immunomagneticallly 
separated luminal and myoepithelial preparations stained 
in the same manner, illustrating their homogeneity in 
respect of cells expressing luminal (CK 18/CK 19) and 
myoepithelial markers (CK 14/vimentin). (b) The irregular 
clusters of cohesive malignant epithelial cells obtained 
when a disaggregated tumour is subject to filtration, 
sedimentation and negative selection for fibroblast 
activation protein-positive reactive stromal cells and 
visualised by phase-contrast microscopy to identify 
samples with minimal microvessel and lymphocytic 
contamination (×400).
See http://www.biomedcentral.com/content/
supplementary/bcr1604-S1.jpegPage 12 of 15
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A Word document showing the pathology of primary 
breast tumours used for MPSS and microarray analysis. 
The pathological information of 15 primary breast 
tumours regarding grade, type, size of vascular invasion, 
lymph node status, estrogen (ER), progesteron (PR) and 




A Word document providing a detailed description of the 
tissue microarray. Summary of clinicopathological 
features of patients included in the tissue microarrays. A 
cohort of 245 invasive breast carcinomas from 245 
patients treated with surgery (wide local excision or 
mastectomy) and adjuvant anthracycline-based 
chemotherapy was retrieved from the Department of 
Histopathology files of the Royal Marsden Hospital with 
appropriate local Ethical Committee approval (Royal 
Marsden Hospital, London, UK). Representative blocks 
from 245 invasive breast carcinomas were reviewed by a 
pathologist (JSRF) and included in duplicate in two 
tissue microarray (TMA) blocks as previously described. 
In brief, 0.6 mm core tissue specimens were taken from 
selected areas of donor blocks (original tumour blocks) 
and precisely arrayed into two new recipient paraffin 
blocks (20 × 35 mm) with a custom-built precision 
instrument (Beecher Instruments, Silver Spring, MD, 
USA). The presence of tumour tissue in the arrayed 
sample was verified on a haematoxylin and eosin stained 
section. ER, PR, p53, vascular invasion, Ki67 (MIB-1) 
labelling index and nodal status were known for all 
samples. Follow up was available for 244 patients, 
ranging from 0.5 to 135.3 months (median = 67.3 




An Excel file listing raw and annotated MPSS data for 
malignant and normal breast epithelial samples. 
Sequence signatures with their corresponding 
annotation and their expression in tpm are shown. 
Transcripts uniquely expressed in the malignant breast 
epithelium and in the normal luminal epithelium are 




An Excel file containing a table showing an overlay of the 
multiple microarray platforms based on the HTR 
database. Microarray featuers of Affymetrix U133 Plus 
2.0 GeneChip and CodeLink™ Human Whole Genome 
Bioarray, Agilent Whole Human Genome Oligo 
Microarray 44 k cDNA array and 20 k brk cDNA 




An Excel file containing a table showing the semi-
quantitative RT-PCR of transcripts belonging to the three 
groups (MPSS-only, MPSS-array confirmed and Array-
only). Transcripts with their respective annotation, RT-
PCR primer sequence and level of expression detected 




An Excel file containing a table showing the differential 
tumour epithelial transcriptome. All 8,051 differentially 
expressed normal luminal versus tumour genes are listed 
with their HTR cluster_ID, microarray_ID and their 
respective fold change for each microarray platform, 





An Excel file containing a table showing the biological 
processes deregulated in the DTET. Biological 
processes of the up- and down-regulated transcripts are 
shown. Gene Ontology identifiers, description, total 
number of input genes, as well as P value are shown. The 
input genes for the most significant deregulated 
biological processes are provided by their gene names 




An Excel file containing a table showing the differential 
normal epithelial transcriptome. Luminal and 
myoepithelial transcriptomes based on multiple 
microarray analyses HTR cluster, microarray feature, fold 
change and P value are listed for each gene.
See http://www.biomedcentral.com/content/
supplementary/bcr1604-S9.xls
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